Everolimus in combination with exemestane and capecitabine BOLERO 6

• Research type

  Research Study

• Full title

  A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole.

• IRAS ID

  122072

• Contact name

  Stephen Chan

• Contact email

  Steve.Chan@nuh.nhs.uk

• Eudract number

  2012-003757-28

• ISRCTN Number

  N/A

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  13/EM/0079

• Date of REC Opinion

  8 May 2013

• REC opinion

  Further Information Favourable Opinion